Novartis study: Nurses and MS patients give thumbs-up to Kesimpta for ease of use

Novartis nabbed FDA approval for Kesimpta to treat multiple sclerosis last year, but now it’s getting the thumbs-up from MS patients and nurses.

Novartis presented study data at the sixth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum in late February showing 84% preferred Kesimpta’s self-administration injector pen over rival administration methods.